Eric Bluestein joined Newmark in 2021 and currently serves as an Executive Managing  Director. Eric brings over 20 years of expertise in sales and leadership positions, and  specializes in representing tenants and landlords in the life sciences and technology  sectors. Eric collaborates with his clients to develop and execute creative real estate  strategies, with a focus on meeting both short and long-term objectives.  

Eric’s diverse client roster includes Arsenal Biosciences, Ascendis Pharma, Bayer  Healthcare, Neuralink, Bristol Myers Squibb, Codexis, Exelixis, RAPT Therapeutics,  23&Me, Veracyte, Madison Reed, NIO, Alexandria, Wareham Development, SKS  Investments. At Newmark, Eric will align with its Capital Markets Northern California  team to augment the firm’s full-scale advisory services within the life science and tech  sectors.

Prior to Newmark, Eric was an Executive Vice President and Shareholder at Kidder  Matthews and a Top 5 Producer from 2015 to 2020.